Publications by authors named "Paolo Cerea"
Article Synopsis
- Guideline-directed therapy for LQTS has changed, with varying ICD recommendations depending on cardiac societies.
- A study analyzed 2861 patients with LQT types to see who met the 2022 guidelines for ICDs and compared outcomes for those with and without an ICD.
- Results showed that while many patients met recommendations for ICDs, more than half did not receive one, and those without an ICD had significantly fewer cardiac events than those with one.
Background: Despite major advances in the clinical management of long QT syndrome, some patients are not fully protected by beta-blocker therapy. Mexiletine is a well-known sodium channel blocker, with proven efficacy in patients with sodium channel-mediated long QT syndrome type 3. Our aim was to evaluate the efficacy of mexiletine in long QT syndrome type 2 (LQT2) using cardiomyocytes derived from patient-specific human induced pluripotent stem cells, a transgenic LQT2 rabbit model, and patients with LQT2.
View Article and Find Full Text PDFBackground And Aims: Risk scores are proposed for genetic arrhythmias. Having proposed in 2010 one such score (M-FACT) for the long QT syndrome (LQTS), this study aims to test whether adherence to its suggestions would be appropriate.
Methods: LQT1/2/3 and genotype-negative patients without aborted cardiac arrest (ACA) before diagnosis or cardiac events (CEs) below age 1 were included in the study, focusing on an M-FACT score ≥2 (intermediate/high risk), either at presentation (static) or during follow-up (dynamic), previously associated with 40% risk of implantable cardioverter defibrillator (ICD) shocks within 4 years.
Background: Predicting an accessory pathway location is extremely important in pediatric patients.
Aims: We designed a study to compare previously published algorithms by Arruda, Boersma, and Chiang.
Methods: This multicenter study included patients who had undergone successful ablation of one accessory pathway.
Do the remodeling effects of sacubitril/valsartan treatment depend upon heart failure duration?
J Cardiovasc Med (Hagerstown)
September 2020
Aims: The angiotensin receptor and neprilysin inhibitor (ARNI) sacubitril/valsartan (LCZ696) is recommended for the treatment of patients with heart failure in New York Heart Association (NYHA) class II-III and left ventricular ejection fraction (LVEF) 35% or less. We examined the effects of sacubitril/valsartan on cardiac remodeling and their correlation with heart failure duration in patients enrolled in our heart failure clinic from March 2017 to December 2019.
Methods: Echocardiographic and clinical/laboratory data were collected at baseline and at 6-month and 12-month follow-up visits in 69 patients (age 67 ± 12 years, disease duration 8.